The Pharmaletter

One To Watch

Arctic Therapeutics

An Icelandic drug discovery and development company established in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG).

In January 2025, Arctic Tx announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of international investors. The proceeds from the Series A financing will be used to advance ATx’s two frontrunners, AT-001 and AT-004, further into clinical trials.

In 2024, the European Medicines Agency approved a pivotal phase IIb/III clinical trial evaluating AT-001 for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare form of familial dementia. The  funding will allow ATx to explore the potential of AT-001, an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain, in other forms of familial dementia, and eventually Alzheimer’s disease.

Want to Update your Company's Profile?


More Arctic Therapeutics news >